Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Rhea-AI Summary
Vir Biotechnology, a commercial-stage immunology company, announced it will provide a corporate update and report financial results for Q4 and full year 2022 on February 23, 2023. The financial results will be accessible via a press release after market close and can be found in the Investors section of their website.
Vir focuses on serious infectious diseases utilizing advanced immunologic technologies. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
Positive
- Ongoing development pipeline targeting serious infectious diseases.
- Focus on innovative immune system enhancement technologies.
Negative
- None.
News Market Reaction – VIR
In the trading session that priced this news, VIR gained 0.66%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
